The epigenetics of prostate cancer diagnosis and prognosis: Update on clinical applications

Current Opinion in Urology

Volumn 25, Issue 1, 2015, Pages 83-88

  Blute, Michael L ^a   Damaschke, Nathan A ^a   Jarrard, David F ^a,b,c  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

^c University of Wisconsin Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTATHIONE TRANSFERASE P1; HISTONE; TUMOR MARKER;

CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER TISSUE; DNA METHYLATION; EPIGENETICS; HISTONE MODIFICATION; HUMAN; PROSTATE BIOPSY; PROSTATE CANCER; PROTEIN DEFECT; REVIEW; SENSITIVITY AND SPECIFICITY; TISSUES; URINE; GENETIC EPIGENESIS; GENETICS; MALE; METABOLISM; PROGNOSIS; PROSTATE; PROSTATIC NEOPLASMS;

BIOMARKERS, TUMOR; DNA METHYLATION; EPIGENESIS, GENETIC; HISTONES; HUMANS; MALE; PROGNOSIS; PROSTATE; PROSTATIC NEOPLASMS;

EID: 84918595101     PISSN: 09630643     EISSN: 14736586     Source Type: Journal    
DOI: 10.1097/MOU.0000000000000132     Document Type: Review

References (46)

1. Fu VX, Dobosy JR, Desotelle JA, et al. Aging and cancer-related loss of insulin like growth factor 2 imprinting in the mouse and human prostate. Cancer Res 2008; 68:6797.
2. Damaschke NA, Yang B, Bhusari S, et al. Epigenetic susceptibility factors for prostate cancer with aging. Prostate 2013; 73:1721.
3. Lee WH, Morton RA, Epstein JI, et al. Cytidine methylation of regulatory sequences near the pi-class glutathione S-trans ferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci U S A 1994; 91:11733.
4. Nakayama M, Gonzalgo ML, Yegnasubramanian S, et al. GSTP1 CpG island hyper methylation as a molecular biomarker for prostate cancer. J Cell Biochem 2004; 91:540.
5. Strand S, Orntoft T, Sorensen K. Prognostic DNA methylation markers for prostate cancer. Int J Mol Sci 2014; 15:16544.
6. Mahon KL, Qu W, Devaney J, et al. Methylated glutathione S-transferase 1 (mGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer. Br J Cancer 2014. [Epub ahead of print].
7. Aoki K, Taketo MM. Adenomatous polyposis coli (APC): A multifunctional tumor suppressor gene. J Cell Sci 2007; 120:3327.
8. Chen Y, Li J, Yu X, et al. APC gene hyper methylation and prostate cancer: A systematic review and meta-analysis. Eur J Hum Genet 2013; 21:929.
9. Richiardi L, Fiano V, Vizzini L, et al. Promoter methylation in APC, RUNX3, and GSTP1 and mortality in prostate cancer patients. J Clin Oncol 2009; 27:3161.
10. Henrique R, Ribeiro FR, Fonseca D, et al. High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients. Clin Cancer Res 2007; 13:6122.
11. Ge YZ, Xu LW, Jia RP, et al. The association between RASSF1A promoter methylation and prostate cancer: evidence from 19 published studies. Tumour Biol 2014; 35:3881.
12. Sørensen KD, Abildgaard MO, Haldrup C, et al. Prognostic significance of aberrantly silenced ANPEP expression in prostate cancer. Br J Cancer 2013; 108:420.
13. Weiss G, Cottrell S, Distler J, et al. DNA methylation of the PITX2 gene promoter region is a strong independent prognostic marker of biochemical recurrence in patients with prostate cancer after radical prostatectomy. J Urol 2009; 181:1678.
14. Yegnasubramanian S, Kowalski J, Gonzalgo ML, et al. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 2004; 64:1975.
15. Truong M, Yang B, Livermore A, et al. Using the epigenetic field defect to detect prostate cancer in biopsy negative patients. J Urol 2013; 189:2335.
16. Alumkal JJ, Zhang Z, Humphreys EB, et al. Effect of DNA methylation on identification of aggressive prostate cancer. Urology 2008; 72:1234.
17. Schayek H, Bentov I, Jacob-Hirsch J, et al. Global methylation analysis identifies PITX2 as an upstream regulator of the androgen receptor and IGF-I receptor genes in prostate cancer. Horm Metab Res 2012; 44:511.
18. Bañez LL, Sun L, van Leenders GJ, et al. Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post radical prostatectomy prostate cancer. J Urol 2010; 184:149.
19. Haldrup C, Mundbjerg K, Vestergaard EM, et al. DNA methylation signatures for prediction of biochemical recurrence after radical prostatectomy of clinically localized prostate cancer. J Clin Oncol 2013; 31:3250.
20. Kobayashi Y, Absher DM, Gulzar ZG, et al. DNA methylation profiling reveals novel biomarkers and important roles for DNA methyl trans ferases in prostate cancer. Genome Res 2011; 21:1017.
21. Mahapatra S, Klee EW, Young CY, et al. Global methylation profiling for risk prediction of prostate cancer. Clin Cancer Res 2012; 18:2882.
22. Lin PC, Giannopoulou EG, Park K, et al. Epigenomic alterations in localized and advanced prostate cancer. Neoplasia 2013; 15:373.
23. Seligson DB, Horvath S, Shi T, et al. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005; 435:1262.
24. Seligson DB, Horvath S, McBrian MA, et al. Global levels of histone modifications predict prognosis in different cancers. Am J Pathol 2009; 174:1619.
25. Halkidou K, Gaughan L, Cook S, et al. Up regulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 2004; 59:177.
26. Huffman DM, Grizzle WE, Bamman MM, et al. SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer Res 2007; 67:6612.
27. Varambally S, Dhanasekaran SM, Zhou M, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002; 419:624.
28. Biancotto C, Frigè G, Minucci S. Histone modification therapy of cancer. Adv Genet 2010; 70:341.
29. Tyler KL, Selvaggi SM. Morphologic features of prostatic adenocarcinoma on Thin Prep urinary cytology. Diagn Cytopathol 2011; 39:101.
30. Ahmed H. Promoter methylation in prostate cancer and its application for the early detection of prostate cancer using serum and urine samples. Bio mark Cancer 2010; 2010:17.
31. Brena RM, Huang TH, Plass C. Quantitative assessment of DNA methylation: potential applications for disease diagnosis, classification, and prognosis in clinical settings. J Mol Med (Berl) 2006; 84:365.
32. Truong M, Yang B, Jarrard DF. Toward the detection of prostate cancer in urine: A critical analysis. J Urol 2013; 189:422.
33. Gonzalgo ML, Pavlovich CP, Lee SM, et al. Prostate cancer detection by GSTP1 methylation analysis of post biopsy urine specimens. Clin Cancer Res 2003; 90:2673.
34. Wu T, Giovannucci E, Welge J, et al. Measurement of GSTP1 promoter methylation in body fluids may complement PSA screening: A meta-analysis. Br J Cancer 2011; 105:65.
35. Rouprêt M, Hupertan V, Yates DR, et al. Molecular detection of localized prostate cancer using quantitative methylation-specific PCR on urinary cells obtained following prostate massage. Clin Cancer Res 2007; 13:1720.
36. Baden J, Green G, Painter J, et al. Multicenter evaluation of an investigational prostate cancer methylation assay. J Urol 2009; 182:1186.
37. Jarrard DF, Bussemakers MJ, Bova GS, et al. Regional loss of imprinting of the insulin-like growth factor II gene occurs in human prostate tissues. Clin Cancer Res 1995; 1:1471.
38. Bhusari S, Yang B, Kueck J, et al. Insulin-like growth factor-2 (IGF2) loss of imprinting marks a field defect within human prostates containing cancer. Prostate 2011; 71:1621.
39. Yang B, Bhusari S, Kueck J, et al. Methylation profiling defines an extensive field defect in histologically normal prostate tissues associated with prostate cancer. Neoplasia 2013; 15:399.
40. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or 1/44.0 ng per milliliter. N Engl J Med 2004; 350:2239.
41. Stewart GD, Van Neste L, Delvenne P, et al. Clinical utility of an epigenetic assay to detect occult prostate cancer in histopathologically negative biopsies: results of the MATLOC study. J Urol 2013; 189:1110.
42. Partin AW, Van Neste L, Klein EA, et al. Clinical validation of an epigenetic assay to predict negative histopathological results in repeat prostate biopsies. J Urol 2014; 192:1081.
43. Van der Auwera I, Van Laere SJ, Van den Bosch SM, et al. Aberrant methylation of the adenomatous polyposis coli (APC) gene promoter is associated with the inflammatory breast cancer phenotype. Br J Cancer 2008; 99:1735.
44. Aubry W. Budget impact model: epigenetic assay can help avoid unnecessary repeated prostate biopsies and reduce healthcare spending. Am Health Drug Benefits 2013; 6:15.
45. Rang FJ, Boonstra J. Causes and consequences of age-related changes in DNA methylation: A role for ROS? Biology (Basel) 2014; 3:403.
46. Kwabi-Addo B, Chung W, Shen L, et al. Age-related DNA methylation changes in normal human prostate tissues. Clin Cancer Res 2007; 13:3796.